Vanda Pharmaceuticals announced the publication of an article titled “The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial” in the Clinical Gastroenterology and Hepatology Journal, which follows a previously published study of tradipitant in the treatment of gastroparesis in 2021. “The findings of this pivotal phase III study are included in the New Drug Application for tradipitant in the treatment of gastroparesis in adults submitted to the U.S. Food and Drug Administration. The FDA has set a Prescription Drug User Fee Act target action date of September 18, 2024 for its decision,” the company stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VNDA:
- Vanda Pharmaceuticals’ IND application for VCA-894A granted FDA approval
- Vanda Pharmaceuticals says court denied in part U.S. motion to dismiss
- Vanda announces publication of journal article on Fanapt study
- Vanda comments on FDA’s recently announced guidance on communication
- Vanda Pharmaceuticals acquires U.S. and Canadian rights to PONVORY
